Literature DB >> 27913496

Discussing and managing hematologic germ line variants.

Wendy Kohlmann1, Joshua D Schiffman1,2.   

Abstract

With the introduction of genomic technologies, more hereditary cancer syndromes with hematologic malignancies are being described. Up to 10% of hematologic malignancies in children and adults may be the result of an underlying inherited genetic risk. Managing these patients with hereditary hematologic malignancies, including familial leukemia, remains a clinical challenge because there is little information about these relatively rare disorders. This article covers some of the issues related to the diagnosis and interpretation of variants associated with hereditary hematologic malignancies, including the importance of an accurate family history in interpreting genetic variants associated with disease. The challenges of screening other family members and offering the most appropriate early malignancy detection is also discussed. We now have a good opportunity to better define hereditary cancer syndromes with associated hematologic malignancies and contribute to clinically effective guidelines.
© 2016 by The American Society of Hematology. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27913496      PMCID: PMC6142475          DOI: 10.1182/asheducation-2016.1.309

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  41 in total

Review 1.  Empirically supported treatments in pediatric psychology: procedure-related pain.

Authors:  S W Powers
Journal:  J Pediatr Psychol       Date:  1999-04

Review 2.  Predisposition to pediatric and hematologic cancers: a moving target.

Authors:  David Malkin; Kim E Nichols; Kristin Zelley; Joshua D Schiffman
Journal:  Am Soc Clin Oncol Educ Book       Date:  2014

3.  BRCA1/2 sequence variants of uncertain significance: a primer for providers to assist in discussions and in medical management.

Authors:  Noralane M Lindor; David E Goldgar; Sean V Tavtigian; Sharon E Plon; Fergus J Couch
Journal:  Oncologist       Date:  2013-04-24

4.  Performance of ACMG-AMP Variant-Interpretation Guidelines among Nine Laboratories in the Clinical Sequencing Exploratory Research Consortium.

Authors:  Laura M Amendola; Gail P Jarvik; Michael C Leo; Heather M McLaughlin; Yassmine Akkari; Michelle D Amaral; Jonathan S Berg; Sawona Biswas; Kevin M Bowling; Laura K Conlin; Greg M Cooper; Michael O Dorschner; Matthew C Dulik; Arezou A Ghazani; Rajarshi Ghosh; Robert C Green; Ragan Hart; Carrie Horton; Jennifer J Johnston; Matthew S Lebo; Aleksandar Milosavljevic; Jeffrey Ou; Christine M Pak; Ronak Y Patel; Sumit Punj; Carolyn Sue Richards; Joseph Salama; Natasha T Strande; Yaping Yang; Sharon E Plon; Leslie G Biesecker; Heidi L Rehm
Journal:  Am J Hum Genet       Date:  2016-05-12       Impact factor: 11.025

5.  Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study.

Authors:  Anita Villani; Uri Tabori; Joshua Schiffman; Adam Shlien; Joseph Beyene; Harriet Druker; Ana Novokmet; Jonathan Finlay; David Malkin
Journal:  Lancet Oncol       Date:  2011-05-19       Impact factor: 41.316

6.  Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors.

Authors:  Bronson D Riley; Julie O Culver; Cécile Skrzynia; Leigha A Senter; June A Peters; Josephine W Costalas; Faith Callif-Daley; Sherry C Grumet; Katherine S Hunt; Rebecca S Nagy; Wendy C McKinnon; Nancie M Petrucelli; Robin L Bennett; Angela M Trepanier
Journal:  J Genet Couns       Date:  2011-12-02       Impact factor: 2.537

7.  Perinatal and familial risk factors for acute lymphoblastic leukemia in a Swedish national cohort.

Authors:  Casey Crump; Jan Sundquist; Weiva Sieh; Marilyn A Winkleby; Kristina Sundquist
Journal:  Cancer       Date:  2014-11-21       Impact factor: 6.860

8.  Guidelines for surveillance of individuals with constitutional mismatch repair-deficiency proposed by the European Consortium "Care for CMMR-D" (C4CMMR-D).

Authors:  H F A Vasen; Z Ghorbanoghli; F Bourdeaut; O Cabaret; O Caron; A Duval; N Entz-Werle; Y Goldberg; D Ilencikova; C P Kratz; N Lavoine; J Loeffen; F H Menko; M Muleris; G Sebille; C Colas; B Burkhardt; L Brugieres; K Wimmer
Journal:  J Med Genet       Date:  2014-02-20       Impact factor: 6.318

9.  Identification of TP53 as an acute lymphocytic leukemia susceptibility gene through exome sequencing.

Authors:  Bradford C Powell; Lichun Jiang; Donna M Muzny; Lisa R Treviño; Zoann E Dreyer; Louise C Strong; David A Wheeler; Richard A Gibbs; Sharon E Plon
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167

10.  Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results.

Authors:  Sharon E Plon; Diana M Eccles; Douglas Easton; William D Foulkes; Maurizio Genuardi; Marc S Greenblatt; Frans B L Hogervorst; Nicoline Hoogerbrugge; Amanda B Spurdle; Sean V Tavtigian
Journal:  Hum Mutat       Date:  2008-11       Impact factor: 4.878

View more
  1 in total

1.  Analysis of 153 115 patients with hematological malignancies refines the spectrum of familial risk.

Authors:  Amit Sud; Subhayan Chattopadhyay; Hauke Thomsen; Kristina Sundquist; Jan Sundquist; Richard S Houlston; Kari Hemminki
Journal:  Blood       Date:  2019-08-08       Impact factor: 22.113

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.